Millennium Management’s Sage Therapeutics SAGE Stock Holding History

Millennium Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-154,500	Closed	-$1.41M	–	6410
2025 Q2	$1.41M	Buy	+154,500	New	+$1.14M	﹤0.01%	4162
2023 Q3	–	Sell	-13,500	Closed	-$635K	–	6502
2023 Q2	$635K	Buy	+13,500	New	+$672K	﹤0.01%	4378
2019 Q4	–	Sell	-25,000	Closed	-$3.51M	–	4578
2019 Q3	$3.51M	Buy	+25,000	New	+$4.18M	0.01%	2067
2019 Q1	–	Sell	-145,100	Closed	-$13.9M	–	4281
2018 Q4	$13.9M	Buy	+145,100	New	+$16.6M	0.02%	932
2016 Q3	–	Sell	-280,000	Closed	-$8.44M	–	3557
2016 Q2	$8.44M	Buy	280,000 +250,000	+833%	+$8.34M	0.02%	955
2016 Q1	$962K	Buy	+30,000	New	+$1.06M	﹤0.01%	2199

Other funds holding SAGE

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Millennium Management's SAGE Position: Q3 2025 in Review

Millennium Management sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 1,002,709 shares — an estimated $9.14M sold.

Millennium Management first reported a position in SAGE in Q3 2014 and held it in 38 quarters. The position peaked at $59.5M in Q2 2018. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

Millennium Management reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
Millennium Management sold 1,002,709 Sage Therapeutics shares in Q3 2025, an estimated $9.14M.
Millennium Management first reported a position in Sage Therapeutics in Q3 2014 and held it in 38 quarters.
Millennium Management's Sage Therapeutics position peaked at $59.5M in Q2 2018.
5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Millennium Management's 13F filing for Q3 2025, filed 14 Nov 2025.